Differential Regulation of Proteasome Function in Isoproterenol-Induced Cardiac Hypertrophy

被引:95
|
作者
Drews, Oliver [1 ]
Tsukamoto, Osamu [3 ]
Liem, David [1 ]
Streicher, John [2 ]
Wang, Yibin [2 ]
Ping, Peipei [1 ]
机构
[1] Univ Calif Los Angeles, Dept Physiol & Med, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Anesthesiol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[3] Natl Cardiovasc Ctr, Dept Cardiovasc Med, Osaka, Japan
关键词
heart disease; protein degradation; cellular homeostasis; LEFT-VENTRICULAR HYPERTROPHY; HEART-FAILURE; OXIDIZED PROTEINS; PRESSURE-OVERLOAD; 20S PROTEASOME; 26S PROTEASOME; INHIBITORS; ACTIVATION; CELLS; IMMUNOPROTEASOME;
D O I
10.1161/CIRCRESAHA.110.222364
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Proteasomal degradation is altered in many disease phenotypes including cardiac hypertrophy, a prevalent condition leading to heart failure. Our recent investigations identified heterogeneous subpopulations of proteasome complexes in the heart and implicated multiple mechanisms for their regulation. Objective: The study aimed at identification of molecular mechanisms changing proteasome function in the hypertrophic heart. Method and Results: Proteasome function, expression, and assembly were analyzed during the development of cardiac hypertrophy induced by beta-adrenergic stimulation. The analysis revealed, for the first time, divergent regulation of proteasome function in cardiac hypertrophy. Proteasome complexes have 3 different proteolytic activities, which are ATP-dependent for 26S complexes (19S assembled with 20S) and ATP-independent for 20S core particles. The 26S activities were enhanced in hypertrophic hearts, partially because of increased expression and assembly of 19S subunits with 20S core complexes. In contrast, caspase-and trypsin-like 20S activities were significantly decreased. Activation of endogenous cAMP-dependent protein kinase (PKA) rescued the depressed 20S functions, supporting the notion that PKA signaling is a positive regulator of protein degradation in the heart. Chymotrypsin-like 20S activity was stably maintained during cardiac remodeling, indicating a switch in proteasome subpopulations, which was supported by altered expression and incorporation of inducible beta subunits. Conclusions: Three novel mechanisms for the regulation of proteasome activities were discovered in the development of cardiac hypertrophy: (1) increased incorporation of inducible subunits in 20S proteasomes; (2) enhanced 20S sensitivity to PKA activation; and (3) increased 26S assembly. PKA modulation of proteasome complexes may provide a novel therapeutic avenue for restoration of cardiac function in the diseased myocardium. (Circ Res. 2010;107:1094-1101.)
引用
收藏
页码:1094 / U91
页数:12
相关论文
共 50 条
  • [31] Combinational effect of resveratrol and atorvastatin on isoproterenol-induced cardiac hypertrophy in rats
    Chakraborty, Songjukta
    Pujani, Mukta
    Haque, Syed Ehtaishamul
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2015, 7 (03): : 233 - 238
  • [32] 4-Chlorodiazepam prevents isoproterenol-induced cardiac hypertrophy in rat
    Maulik, S. K.
    Seth, S.
    Dinda, A. K.
    Jaiswal, A.
    CARDIOVASCULAR RESEARCH, 2012, 93 : S124 - S124
  • [33] Isoproterenol-induced Cardiac Hypertrophy And Failure In Mice: Gene Network Modeling
    Rau, Christoph D.
    Wang, Jessica
    Ren, Shuxun
    Wang, Zhihua
    Ruan, Hongmei
    Wang, Yibin
    Lusis, Aldons J.
    CIRCULATION RESEARCH, 2013, 113 (04)
  • [34] Original Protective effect of sinomenine on isoproterenol-induced cardiac hypertrophy in mice
    Li, Le
    Fang, Pu
    Chen, Jiekun
    Zhang, Cailing
    Tao, Houquan
    JOURNAL OF APPLIED BIOMEDICINE, 2021, 19 (03) : 142 - 148
  • [35] ISOPROTERENOL-INDUCED CARDIAC NECROSIS
    KAHN, DS
    RONA, G
    CHAPPEL, CI
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1969, 156 (A1) : 285 - &
  • [36] TAURINE UPTAKE IN MOUSE CARDIAC SLICES AND MODIFICATION BY ISOPROTERENOL-INDUCED CARDIAC-HYPERTROPHY
    HIRAI, K
    YONEDA, Y
    KURIYAMA, K
    FOLIA PHARMACOLOGICA JAPONICA, 1979, 75 (01) : P15 - P16
  • [37] AT1 receptor mediates isoproterenol-induced cardiac hypertrophy and oxidative stress
    Tajima, S
    Tsutiya, K
    Ohnishi, H
    Kanematsu, Y
    Yoshizumi, M
    Tamaki, T
    Mason, R
    Takiguti, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 62P - 62P
  • [38] Differential activation of Ras/Raf/MAPK pathway between heart and cerebral artery in isoproterenol-induced cardiac hypertrophy
    Hyunju, Kim
    Nari, Kim
    Boum, Youm Jae
    Joo, Hyun
    Park, Won Sun
    Warda, Mohammad
    Kim, Euiyong
    Moon, Hyejin
    Lee, Hyunsuk
    Kang, Sunghyun
    Kim, Hyungkyu
    Kim, Taeho
    Han, Jin
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 176 - 176
  • [39] Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg
    Han, Xiongyi
    Bai, Liyan
    Kee, Hae Jin
    Jeong, Myung Ho
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (14) : 4076 - 4086
  • [40] The mitochondrial metabolic phenotype and mouse strain influence isoproterenol-induced cardiac hypertrophy
    Faulx, M
    Zawaneh, MS
    Chandler, MP
    Stanley, WC
    Holt, BD
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (05) : 156A - 156A